Petty, W.J., Dragnev, K.H., Memoli, V.A., Ma, Y., Desai, N.B., Biddle, A., Davis, T.H., Nugent, W.C., Memoli, N., Hamilton, M., Iwata, K.K., Rigas, J.R. and Dmitrovsky, E.
Notes: The CellTiter-Glo® Luminescent Cell Viability Assay was used to examine the proliferation of BEAS-2B (immortalized human bronchial epithelial (HBE)) cells after treatment with various concentrations of erlotinib, an inhibitor of the mitogenic effects of EGF. For these experiments, 3,000/well were seeded in 96-well plates and incubated for 72 hours with various concentrations of erlotinib. Other lung cell carcinoma cell lines (A549, H226, H358, and H441) were also tested for proliferation in the presence of erlotinib using the CellTiter-Glo® Assay system. The researchers used a luciferase construct that contained the cyclin D1 promoter to test the effects of erlotinib on cyclin d1 regulation. This construct, along with the pRL-TK vector, were co-transfected into BEAS-2B cells. Groups of cells were then treated with or without EGF and erlotinib and assayed for luciferase activity using the Dual-Luciferase® Reporter Assay System. (3258)